Metroplex Clinical Research Center
Dallas, Texas, United States
Roy Fleischmann is an Adjunct Professor of Medicine at the University of Texas Southwestern Medical Center and Medical Director of the Metroplex Clinical Research Center in Dallas, Texas, USA. He received his MD from the State University of New York, Downstate Medical Center, and completed his residency in medicine at Mount Sinai Medical Center in New York City. His fellowship in rheumatology was completed at the College of Physicians and Surgeons of Columbia University, New York. He was elected a Master of the American College of Rheumatology (ACR) in 2010.
Professor Fleischmann has authored over 300 manuscripts and more than 500 abstracts, focusing on the management of rheumatoid arthritis, which have been published in leading international peer-reviewed journals, and presented at prestigious rheumatology meetings worldwide. With more than 40 years of experience as a clinical investigator, Professor Fleischmann has been a principal or co-principal investigator in over 1,000 clinical studies in the field of rheumatology. He has presented frequently at the ACR and EULAR Annual Meetings and is Editor of Rheumatology and Therapy and on the Editorial Board of the Annals of Rheumatic Disease, RMD OPen, Journal of Rheumatology and Expert Opinion on Drug Safety. He has served as a reviewer for many peer-reviewed journals including Arthritis & Rheumatism, Annals of Rheumatic Disease, Lancet, the New England Journal of Medicine and the Journal of Rheumatology
Sunday, October 26, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): ,Immunovant: Consultant (Ongoing); AbbVie: Consultant (Ongoing); Almirall: Consultant (Ongoing); Artiva Biotherapeutics: Consultant (Ongoing); Atomwise,: Consultant (Ongoing); Biohaven: Consultant (Ongoing); BMS: Consultant (Ongoing); Cyoxone,: Consultant (Ongoing); Deep Cure: Consultant (Ongoing); Dren Bio: Consultant (Ongoing); Eisai: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Galvani: Consultant (Ongoing); Gates Bio: Consultant (Ongoing); Gilead: Consultant (Ongoing); GSK: Consultant (Ongoing); Halia: Consultant (Ongoing); ImmuneMed: Consultant (Ongoing); InventisBio: Consultant (Ongoing); Istesso: Consultant (Ongoing); Janssen: Consultant (Ongoing); Janux: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Monte Rosa: Consultant (Ongoing); Novartis: Consultant (Ongoing); Overland: Consultant (Ongoing); Pfizer: Consultant (Ongoing); Roche: Consultant (Ongoing); RPharma: Consultant (Ongoing); Synact: Consultant (Ongoing); TPG: Consultant (Ongoing); UCB: Consultant (Ongoing); Vyne: Consultant (Ongoing); Xencor: Consultant (Ongoing)
Monday, October 27, 2025
1:30 PM - 1:45 PM Central Time
Disclosure(s): ,Immunovant: Consultant (Ongoing); AbbVie: Consultant (Ongoing); Almirall: Consultant (Ongoing); Artiva Biotherapeutics: Consultant (Ongoing); Atomwise,: Consultant (Ongoing); Biohaven: Consultant (Ongoing); BMS: Consultant (Ongoing); Cyoxone,: Consultant (Ongoing); Deep Cure: Consultant (Ongoing); Dren Bio: Consultant (Ongoing); Eisai: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Galvani: Consultant (Ongoing); Gates Bio: Consultant (Ongoing); Gilead: Consultant (Ongoing); GSK: Consultant (Ongoing); Halia: Consultant (Ongoing); ImmuneMed: Consultant (Ongoing); InventisBio: Consultant (Ongoing); Istesso: Consultant (Ongoing); Janssen: Consultant (Ongoing); Janux: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Monte Rosa: Consultant (Ongoing); Novartis: Consultant (Ongoing); Overland: Consultant (Ongoing); Pfizer: Consultant (Ongoing); Roche: Consultant (Ongoing); RPharma: Consultant (Ongoing); Synact: Consultant (Ongoing); TPG: Consultant (Ongoing); UCB: Consultant (Ongoing); Vyne: Consultant (Ongoing); Xencor: Consultant (Ongoing)
